Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Lite Strategy, Inc. LITS NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
50/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Lite Strategy, Inc. (LITS) is a Biotechnology company in the Healthcare sector, currently trading at $1.20. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Valuation: LITS trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $16M (loss), growing at +2.6%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $0 against $17M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.5 (strong liquidity). Debt-to-assets is 0%. Total assets: $18M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future ?/100 (Fail), Income ?/100 (Fail).

LITS SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LITS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
30/100
LITS: -15.4%/yr revenue is, +2.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
LITS: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet LITS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.5 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
LITS: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.95-9
Volume91.31K
Avg Volume (30D)334.02K
Market Cap$44.12M
Beta (1Y)0.10
Share Statistics
EPS (TTM)-2.39
Shares Outstanding$6.66M
IPO Date2003-12-18
Employees4
CEOJustin J. File
Financial Highlights & Ratios
Gross Profit$-368K
EBITDA$-17.09M
Net Income$-15.95M
Operating Income$-17.46M
Total Cash$18.01M
Net Debt$-18.01M
Total Assets$18.29M
Price / Earnings (P/E)-0.5
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS55279B3015

Price Chart

Track all markets on TradingView
LITS
Lite Strategy, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.95 52WK RANGE 9.00

People Also View

RLMD
RLMD
Relmada Therapeutics, Inc.
$7.18
-0.14%
 IMUX
IMUX
Immunic, Inc.
$1.11
-5.93%
 ACET
ACET
Adicet Bio, Inc.
$7.92
+13.14%
 PMVP
PMVP
PMV Pharmaceuticals, Inc.
$1.41
-4.08%
 XBIT
XBIT
XBiotech Inc.
$2.46
+1.23%
 TCRX
TCRX
TScan Therapeutics, Inc.
$1.07
+0.94%
 ACRV
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.67
+1.83%
 NTRB
NTRB
Nutriband Inc.
$4.08
+0.49%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message